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I.  GENERAL 
The present directive, which,  is  complementary 
to  the  directive  issued  by  the  Council  of 
Ministers  on  5  November  1962,  is  intended 
to  amplify  it  by  laying  down  certain  provi-
sions  concerning the testing  of branded  phar-
maceuticals. 
As  stated  in the  explanatory memorandum of 
the first  directive,  the problem of tests  is  one 
of the most  important that have  to  be  solved 
before  there  can  be  fuller  harmonization 
of the regulations governing the offer for sale 
of  branded  pharmaceuticals  in  the  Member 
States. 
In  making  the  present  proposal  the  Com-
mission  is  acting  in  response  to  the  recom-
mendations  of  the  European  Parliament  and 
the  Economic  and  Social  Committee  which, 
on  being consulted concerning the text  of the 
first  directive,  urged  the  Executive  to  pursue 
the  work  of  harmonization  that  had  been 
undertaken  in this  field. 
The  aim  of  this  second  directive  is,  in  fact, 
to  narrow  the  more  outstanding  disparities 
between  the  regulations  applicable  in  the 
different  Member  States,  and  so  to  facilitate 
the  mutual  recognition  of licences  for  sale  of 
branded  pharmaceuticals,  which  is  the  ulti-
mate  objective. 
This  directive  contains  two  sets  of  provisions 
prompted by two distinct, but complementary, 
considerations.  It defines the obligations  laid 
upon  manufacturers  of  branded  pharmaceu-
ticals  by  way  of  guaranteeing  the  quality  of 
their  products,  both  at  the  production  stage 
and  at  the time when the application  is  made 
for a licence for sale.  The relevant  provisions 
are  contained  in  Chapters  I  and  III. 
It was  also  considered  necessary  to define  the 
scope  of  the  functions  of  administrative 
bodies  responsible for  the protection of public 
health.  These  are  concerned  with: 
1)  Action  taken  before  the  licence  for  sale 
is  issued,  and  in  particular  the  examination 
of the application,  so  as  to  make  certain  that 
the  conditions  for  granting  these  licences,  as 
set  out in the directive  of 5  November  1962, 
have  been  fulfilled. 
2)  General  supervision  by  the  authorities 
during  the  manufacturing  process  and  when 
the  branded  pharmaceuticals  are  offered  for 
sale. 
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The  relevant  provisions  are  contained  in 
Chapters  II  and  IV. 
The  directive  also  contains  special  provisions 
concerning  notification  of  the  competent 
authorities' decisions to the persons concerned, 
and  the  communication  of  certain  of  these 
decisions  to  the  authorities  in  other  Member 
States:  these  provisions  are  contained  in 
Chapter  V. 
Finally  the  directive  contains  provisions 
concerning  implementation  and  transitional 
arrangements;  among  these,  Article  13  is  of 
special  importance.  It  is  examined  in  the 
second  part of this Explanatory Memorandum, 
in  which  the  directive  is  discussed  in  detail 
article  by  article. 
II.  COMMENTARY  ON  THE  ARTICLES 
Chapter 
Application  for  licence  for  sale 
The  provisions  in  this  chapter  are  comple-
mentary to those in the directive of 5 Novem-
ber  1962.  In particular,  the  chapter contains 
certain  detailed , regulations  concerning  the 
documentation  to  be  submitted  in  accordance 
with  Article  4  of  that  directive. 
Article  1 
Under the  terms  of this  article,  the manufac-
turer  or  any  other  person  applying  for  a 
licence  to sell  a  branded pharmaceutical must 
submit  to  experts,  whom  he  may  nominate, 
the  documents  specified  in  Article  4  of  the 
first  directive, points 7 and  8.  These concern 
the  methods  of testing  used  by  the  manufac-
turer,  and  the  results  of  various  trials  made 
by  him before deciding to market the product. 
It should  be  noted  that  while  the  manufac-
turer  has  the  prerogative  of  choosing  the 
experts, he is  not entirely free, in that he may 
only choose persons with a certain competence 
in  this  field,  and  the  authorities  have  the 
power  not  to  approve  this  choice  if  the 
expert  is  not  sufficiently  competent. 
Article 2 
This  article  sets  out  the  functions  of  the 
experts mentioned  in Article  1. 
Their first  duty is  to give  an  opinion on the 
testing methods used  by the manufacturer and 
on  the  results  they  yield. The  object  is  to  ensure  that  the  manufac-
turer's  methods  provide  a  satisfactory  test  of 
the  product. 
Secondly,  the  experts  are  asked  to  give  their 
opinion  on  the  trials  the  manufacturer  has 
carried  out  to  prove  the  harmlessness  of  the 
product  and  its  therapeutic  potency. 
Article  3 
The  intention  of  this  provlS!on  is  clear. 
Failure  to  observe  the  provisions  laid  down 
in  Articles  1  and  2  will  incur  the  same 
penalty  as  failure  to  comply  with  the  rules 
laid  down  in  Article  4  of  the  first  directive 
concerning  the  documentation  submitted  in 
support  of  the  application  for  a  licence:  this 
penalty consists in rejection ot the application. 
The  severity  of  the  penalty  underlines  the 
importance  attached  to  the  work  of  the 
experts 
Chapter  II 
Examination  of  the  application  for  a 
licence  for  sale 
This  chapter deals  with  the  powers  vested  in 
national  authorities  to  satisfy  themselves  that 
branded  pharmaceuticals  fulfil  the  conditions 
laid down. 
Article 4 
This  article  deals  with  the  powers  of exami-
nation  enabling  the  authority  to  decide 
whether to  grant  a  licence  or  refuse  it. 
These  powers  include  in  the  first  place  the 
examination of documents, including opinions 
given  by  the  experts.  If  on  examination 
it is  found that the conditions for  obtaining a 
licence  have  not  been  fulfilled,  the  authority 
is  obliged  to  withhold  the  licence.  It  is 
possible,  however,  that  the  documents  sup-
plied  by  the applicant may  have  an  omission 
or  leave  room  for  doubt  on  certain  points. 
If such  shortcomings  are  not  of  overriding 
importance in  assessing  the documentation,  it 
would ,appear excessive  for  a  refusal to follow 
automatically.  Allowance  has  therefore  been 
made  for  supplementary  information  or tests 
to be requested from the manufacturers.  This 
option  should  only  be  used  in  exceptional 
cases  at  the discretion of the authorities. 
Provision  is  also  made  whereby  the  compe-
tent authorities may use  their discretion, again 
in  exceptional  cases,  to  order  the  tests  to  be 
repeated  by  a  government  laboratory  or  a 
laboratory  chosen  by  them,  by  the  same 
methods  as  the  manufacturer  claims  to  have 
used.  In  this  way  the authority, should there 
be  any  doubt,  can  satisfy  itself  that  the  pro-
duct  conforms  to  the stated  formula. 
Article 5 
Under  this  article  the  competent  author-
ities  must  ascertain  that  the  manufacturers 
possess  the  testing  facilities  necessary  to  use 
the  methods  described  in  the  documentation. 
Although  this  checking  by  the  authorities  is 
prescribed  by  law  in  some  countries  as  part 
of  the  procedure  for  licences  to  manufacture 
medicinal  products,  it  was  considered  neces-
sary,  pending  the  harmonization  of  national 
regulations  on  this  point,  to  include  the 
principle  in  the  present  directive.  The  rule 
is  that the manufacturer musr himself possess, 
that  is  to  say  on  his  own  premises,  these 
testing  facilities. 
However,  in  special  cases  and  on  adequate 
grounds,  the  competent  authority  may  grant 
exemption  from  this  regulation,  the  testing 
then  being  carried  out  by  a  specialized 
laboratory. 
Chapter  III 
Testing  of  the  branded  pharmaceutical 
by  the  manufacturer 
Article 6 
This provision  is  an  extension  of Article 8  of 
the  directive  of  5  November  1962,  which 
makes  it compulsory for  the manufacturer  to 
carry out tests on finished products and supply 
proof  that  they  have  been  carried  out. 
Article  6  of  the  present  directive  extends 
this  obligation  to  carrying  out  tests  on  the 
raw  materials  used,  and  on  products  during 
manufacture, when the nature of the products 
makes  this  necessary. 
Article 7 
As  in  the  provlS!ons  of  the  directive  of 
5  November  1962 in  respect  of infringement 
of  Article  8  thereof,  failure  to  meet  the 
requirements  of  Article  6  involves  penalties. 
These  penalties  are,  however,  different  from 
those  laid  down  in  the  first  directive,  since 
infringement  of  Article  6  of  the  present 
directive is  less  serious.  Failure  to carry  out 
or furnish  proof of tests  on finished  products 
incurs  the  withdrawal  or  suspension  of  the 
licence  for  sale;  the  penalty  for  failure  to 
carry  out  or  furnish  proof  of  tests  on  raw 
materials  or  during  manufacture,  will  only 
be an  order to cease or suspend production. 
3 Chapter  IV 
Supervision 
This  chapter  deals  with  the  general  supe_r-
visory  duties  of  public  health  authorities  10 
connection  with  the  manufacture  and  sale  of 
branded  pharmaceuticals. 
Article 8 
The  first  paragraph  states  the  object  of 
inspections,  which  is  to  ensure  that  the legal 
provisions  governing the  production  and  sale 
of  branded  pharmaceuticals  are  observed. 
The  persons  carrying  out  these  inspections 
must  be  members  of  the  authority's  staff. 
Their powers  are  specified  in  the third  para-
graph.  It is  laid  down  that  these  inspectors 
must  have  access  to  the  manufacturing 
establishments,  and  also,  when  certain  tests 
are  carried  out  outside,  in  accordance  with 
Article  5(2),  to  the laboratories  carrying  out 
these  tests;  they  may  take  samples,  and 
examine  any  documents  relevant  to  the 
inspection.  The  right  to  obtain  information 
on  the  manner  in  which  the  product  is 
prepared  has,  however,  been  kept  within 
limits;  in  order  to  safeguard  manufacturing 
secrets,  this  power  is  limited  to  the  descrip-
tions  given  by  the  manufacturers  in  their 
application  for  a  licence  for  sale. 
Article  9 
This is  a measure to prevent branded pharma-
ceuticals  already  on  the market  from  continu-
ing to be  distributed when they have incurred 
a  penalty  as  provided  in  the  directive  of 
5  November 1962 or in the present directive. 
Chapter  V 
Miscellaneous 
Article  10 
This  article  does  not  appear  to  call  for  any 
special  comment. 
Article  11 
This  article  does  not  appear  to  call  for  any 
special  comment. 
Article  12 
This  article  provides  for  exchange  of  infor-
mation  between  national  authorities  on  the 
more  important  decisions  which  they  are 
called  upon  to  take  concerning  the  sale  of 
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branded  pharmaceuticals,  so  as  to  avoid 
discrepancies  and  possible  repercussions 
thereof.  This  provision  has  been  introduced 
in  response  to  the  recommendations  of  the 
Economic and  Social  Committee  (see  Opinion 
of  25  April  1963  - doc.  18/3)  and  inter-
national  organizations  such  as  the  World 
Health  Organization  and  the  Council  of 
Europe. 
This  provision  can  also  be  considered  as 
inaugurating  closer  co-operation  between 
national  authorities. 
Chapter  VI 
Implementing  arrangements  and  transi-
tional measures 
Article  13 
The  need  for  general  quality  standards  for 
medicinal  preparations  (as  regards  purity, 
stability,  etc.),  has  been  stressed  on  several 
occasions.  Concurrently with work being done 
by  the  W odd  Health  Organization  and  the 
Council  of  Europe,  the  Commission  has 
undertaken  the  preparation  of  a  European 
pharmacopoeia. 
The Commission  also  felt  it  desirable  to  take 
the  initiative  of  studying,  in  collaboration 
with the competent authorities of the Member 
States  and  with  the  assistance  of  scientific 
circles  in  the  Community,  standardized 
methods  for  carrying  out  various  tests  on 
medicinal  products  (physico-chemical,  biolo-
gical,  microbiological,  pharmacological,  toxi-
cological  and  clinical  tests),  and  for  evaluat-
ing their results. 
Two interconnected series of studies are conse-
quently  in  progress,  the  results  of  which 
should  have a  favourable  influence from  both 
the  public  health  and  economic  points  of 
v1ew. 
From  the  public  health  angle,  the  work  on 
the  pharmacopoeia  and  on  test  procedures  is 
unquestionably  of  interest,  because  of  •the 
advantages  and  guarantees  that  any  normal-
ization  brings  to  the  scientific  sector,  and 
also  because  these  studies  will  enable  all 
manufacturers  of  pharmaceuticals  in  the 
Community to make use of the most advanced 
technical  knowledge. 
On  the  economic  side,  the  compilation  of  a 
pharmacopoeia  will  be  particularly  valuable 
as  regards  rationalizing  production;  so  far  as 
test  procedures  are  concerned,  they  will 
enable those  who carry  out tests  of  medicinal 
products  to  know  the  rules  for  carrying  out 
tests  (their duration,  the means  applied, etc.) 
and  for  assessing  and  presenting  the  results. All  this  work  will  also  add  to  the  efficiency 
of the competent authorities' tests of medicinal 
products,  and  to  a  large  extent  avoid  discre-
pancies  in  assessing  the  results  of  tests  sub-
mitted  with  an  application  for  a  licence  to 
sell  a  branded  pharmaceutical. 
Establishing  the  standards  and  procedures 
provided  for  in this  article  will call  for  com-
plex  studies  over  a  long  period.  Continual 
revision  will  also  be  necessary.  However,  it 
seemed  advisable  to  stress  the  gradual  nature 
of  this  work  and  the  need  to  apply  the  first 
results  as  soon  as  possible,  in  the  interests 
of both public health  and  production,  by  set-
ting  a  date  for  the  first  phase. 
Article 14 
Paragraph 1  of this  article does  not appear to 
call  for  any  special  comment.  Paragraph  2 
was  included  to  enable  the  Commission  to 
be  informed  reasonably  promptly of any  plan 
drawn  up  by  Member  States  in  the  fields 
covered  by  the  present  directive,  so  that  the 
Commission  may  present  its  comments. 
Article  15 
This  article  does  not  appear  to  call  for  any 
special  comment. 
Article  16 
This  article  does  not  appear  to  call  for  any 
special  comment. 
Proposal for a second directive on the harmonization of laws and regulations 
governing  pharmaceutical  products 
(Submitted  by  the Commission to the Council) 
The Council  of the European  Economic Com-
munity, 
Having regard to  the provisions of the Treaty 
establishing  the  European  Economic  Commu-
nity,  and  particularly  Articles  100  and  155 
thereof; 
Having regard to  the directive on  the harmo-
nization  of  laws  and  regulations  governing 
pharmaceutical products of 5 November 1962; 
Haz;ing  regard  to  the  proposal  of  the  Com-
mission; 
Haz;ing  regard to  the opinion of the European 
Parliament; 
Having regard to  the opinion of the Economic 
and  Social  Committee; 
Whereas  disparities  in  certain  national  laws 
have  the effect  of hindering trade  in  pharma-
ceutical  products  within  the  Community,  and 
whereas  this  affects  the  establishment  and 
operation  of the  Common  Market; 
Whereas  the  directive  of  5  November  1962 
laid  down  certain  principles  with  a  view  to 
achieving  the  harmonization of laws  concern-
ing the sale  of  branded  pharmaceuticals; 
Whereas  it is  important to pursue the harmo-
nization  begun  by  the directive  of  5  Novem-
ber  1962  and  to  ensure  that  the  principles 
laid  down  by  that  directive  are  applied; 
Whereas  among  the  remaining  disparities, 
those  affecting  the  testing  of  branded  phar-
maceuticals  are  of  primary  importance; 
Whereas with a view to reducing these dispar-
ities,  it  is  important  to  establish  rules  which 
manufacturers  of  branded  pharmaceuticals 
must observe  in testing their products, and to 
define the duties to  be carried out by  national 
authorities  to  ensure  that  legal  require-
ments  are  observed; 
Where  as  so  as  to  ensure  the  operation  and 
development  of  the  Common  Market  the 
Commission  must  be  able  to  exercise  certain 
powers  for  the  execution  of  the  directive  of 
5  November  1962, 
Has  issued the  present  directive: 
Chapter 
Application  for  licence  for  sale 
Article 1 
Member  States  shall  take  the  necessary 
measures  to  ensure  that  the  particulars  and 
supporting  documents  referred  to  in  Arti-
cle  4(2),  points  7  and  8  of  the  directive  of 
5  November  1962  shall  be  referred  by  the 
applicant  to  experts  having  the  necessary 
technical  or  professional  qualifications  before 
being submitted  to  the  competent  authorities. 
Article 2 
The experts  mentioned in Article  1 shall give 
their  opinion: 
1.  On  the  methods  of  testing  referred  to  m 
Article  4 (  2),  paint  7  of  the  directive  of 
5 All  this  work  will  also  add  to  the  efficiency 
of the competent authorities' tests of medicinal 
products,  and  to  a  large  extent  avoid  discre-
pancies  in  assessing  the  results  of  tests  sub-
mitted  with  an  application  for  a  licence  to 
sell  a  branded  pharmaceutical. 
Establishing  the  standards  and  procedures 
provided  for  in this  article  will call  for  com-
plex  studies  over  a  long  period.  Continual 
revision  will  also  be  necessary.  However,  it 
seemed  advisable  to  stress  the  gradual  nature 
of  this  work  and  the  need  to  apply  the  first 
results  as  soon  as  possible,  in  the  interests 
of both public health  and  production,  by  set-
ting  a  date  for  the  first  phase. 
Article 14 
Paragraph 1  of this  article does  not appear to 
call  for  any  special  comment.  Paragraph  2 
was  included  to  enable  the  Commission  to 
be  informed  reasonably  promptly of any  plan 
drawn  up  by  Member  States  in  the  fields 
covered  by  the  present  directive,  so  that  the 
Commission  may  present  its  comments. 
Article  15 
This  article  does  not  appear  to  call  for  any 
special  comment. 
Article  16 
This  article  does  not  appear  to  call  for  any 
special  comment. 
Proposal for a second directive on the harmonization of laws and regulations 
governing  pharmaceutical  products 
(Submitted  by  the Commission to the Council) 
The Council  of the European  Economic Com-
munity, 
Having regard to  the provisions of the Treaty 
establishing  the  European  Economic  Commu-
nity,  and  particularly  Articles  100  and  155 
thereof; 
Having regard to  the directive on  the harmo-
nization  of  laws  and  regulations  governing 
pharmaceutical products of 5 November 1962; 
Haz;ing  regard  to  the  proposal  of  the  Com-
mission; 
Haz;ing  regard to  the opinion of the European 
Parliament; 
Having regard to  the opinion of the Economic 
and  Social  Committee; 
Whereas  disparities  in  certain  national  laws 
have  the effect  of hindering trade  in  pharma-
ceutical  products  within  the  Community,  and 
whereas  this  affects  the  establishment  and 
operation  of the  Common  Market; 
Whereas  the  directive  of  5  November  1962 
laid  down  certain  principles  with  a  view  to 
achieving  the  harmonization of laws  concern-
ing the sale  of  branded  pharmaceuticals; 
Whereas  it is  important to pursue the harmo-
nization  begun  by  the directive  of  5  Novem-
ber  1962  and  to  ensure  that  the  principles 
laid  down  by  that  directive  are  applied; 
Whereas  among  the  remaining  disparities, 
those  affecting  the  testing  of  branded  phar-
maceuticals  are  of  primary  importance; 
Whereas with a view to reducing these dispar-
ities,  it  is  important  to  establish  rules  which 
manufacturers  of  branded  pharmaceuticals 
must observe  in testing their products, and to 
define the duties to  be carried out by  national 
authorities  to  ensure  that  legal  require-
ments  are  observed; 
Where  as  so  as  to  ensure  the  operation  and 
development  of  the  Common  Market  the 
Commission  must  be  able  to  exercise  certain 
powers  for  the  execution  of  the  directive  of 
5  November  1962, 
Has  issued the  present  directive: 
Chapter 
Application  for  licence  for  sale 
Article 1 
Member  States  shall  take  the  necessary 
measures  to  ensure  that  the  particulars  and 
supporting  documents  referred  to  in  Arti-
cle  4(2),  points  7  and  8  of  the  directive  of 
5  November  1962  shall  be  referred  by  the 
applicant  to  experts  having  the  necessary 
technical  or  professional  qualifications  before 
being submitted  to  the  competent  authorities. 
Article 2 
The experts  mentioned in Article  1 shall give 
their  opinion: 
1.  On  the  methods  of  testing  referred  to  m 
Article  4 (  2),  paint  7  of  the  directive  of 
5 5  November  1962  and  the  results  obtained 
by  these  methods: 
2.  On  the  results  of  physico-chemical,  biolo-
gical,  micro-biological,  pharmacological,  toxi-
cological  and  clinical  tests  carried  out. 
Article 3 
In the event of infringement of the provisions 
of  Articles  1  and  2  of  the  present  directive, 
Article  5(2)  of  the  directive  of  5  Novem-
ber  1962  shall  be  applicable. 
Chapter  II 
Examination  of  application  for  licence 
for  sale 
Article 4 
The  Member  States  shall  take  the  necessary 
measures  to ensure that the competent author-
ities  shall,  within  the  time-limits  laid  down 
in  Article  7,  paragraph  1,  point 2,  and  para-
graph 2  of the directive of 5 November 1962 
examine  the  application  in  order  to  satisfy 
themselves  that  the  conditions  for  obtaining 
a licence  for  sale  have  been  fulfilled. 
To  this  end,  the  competent  authorities: 
1.  Shall  check  the  particulars  submitted  m 
accordance  with  Article  4  of  the  directive  of 
5  November  1962  and  shall  verify  that  the 
.opinions  given  by  the  experts  in  accordance 
with  Article  2  of  the  present  direGive  are 
comprehensive  and  conclusive; 
2.  May  request  the  manufacturer  to  supply 
additional  information  or carry out additional 
tests; 
3.  May  submit the  product  to  a  State  labora-
tory  or  a  laboratory  designated  for  this 
purpose to  repeat  the tests  carried  out by  the 
manufacturer, by  the methods described in the 
documentation  in  accordance  with  Arti-
cle  4(2),  point  7,  of  the  directive  of  5  No-
vember  1962. 
When  the  competent  authorities  exercise  the 
preroga:ive  mentioned  in  point  2  of  the 
foregoing  paragraph,  the  time-limits  laid 
down  in  Article  7,  paragraph  1,  point 2  and 
paragraph  2  of the  directive  of  5  November 
1962  shall  be  waived. 
Article 5 
The  Member  States  shall  take  the  necessary 
measures  for  the  competent  authorities  to 
check  that  the  manufacturers  are  able: 
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1.  To make the tests  by  the methods described 
in  the documentation  and  mentioned  in  Arti-
cle  4(2),  point  7,  of  the  directive  of  5  No-
vember  1962; 
2.  In  exceptional  cases,  good  cause  being 
shown and provided the competent authorities 
are  in  agreement,  to  have  some  of  the  tests 
prescribed  in  point  1  above  carried  out  on 
their  own  responsibility. 
Chapter  III 
Tests  of  branded  pharmaceuticals 
by  the manufacturer 
Article 6 
The  Member  States  shall  take  the  necessary 
steps  to  ensure  that  the  holder  of  a  licence 
to  sell  a  branded  pharmaceutical  shall  be 
obliged  to  furnish  proof,  whenever  requested, 
that  tests  on  raw  materials  have  been  carried 
out and  also  tests  in the course  of  production 
in  so  far  as  the  latter  are  necessary  for  a 
manufacturing process  in accordance  with  the 
regulations  in  force. 
Article 7 
The  Member  States  shall  take  the  necessary 
steps  to  ensure  that  the  production  of  a 
branded  pharmaceutical  shall  be  temporarily 
or  permanently  stopped  if,  after  receiving  a 
formal  notice,  the  holder  of  the  licence  for 
sale  cannot  furnish  the  proof  specified  in 
Article  6. 
Chapter  IV 
Supervision 
Article 8 
The  competent  authorities  shall  ensure  by 
carrying  out  inspections  that  the  regulations 
concerning the production and sale of branded 
pharmaceuticals  are complied  with. 
The  inspections  referred  to  in  the  foregoing 
paragraph  shall  be  carried  out  by  the  appro-
priate personnel  of  the competent authorities. 
The  above-mentioned  personnel  must  be 
empowered: 
1.  To visit  manufacturing  establishments  and 
laboratories  responsible  for  carrying  out  tests 
on  behalf  of  the  manufacturer  in  accordance 
with  the  provisions  of  Article  5,  point  2; 
2.  To  take  samples; 3.  To take  note  of  all  documents  relevant  to 
the  object  of  the  inspections,  apart  from 
descriptions  of  methods  of  preparation  when 
these  descriptions  go  beyond  those  contained 
in  the documentation submitted in  support of 
the  application  for  a  licence  for  sale  in 
accordance  with Article  4(2), point  4,  of the 
directive  of  5  November  1962. 
Article 9 
The  Member  States  shall  take  the  necessary 
measures  to  ensure  that  deliveries  of  the 
branded  pharmaceutical  shall  be  forbidden 
and  that the product shall be  withdrawn from 
the  market,  in  cases  where: 
1.  When  used  under  normal  conditions,  the 
product  appears  to  be  harmful; 
2.  The  product  is  deficient  in  therapeutic 
potency  or  the  applicant  supplies  inadequate 
proof  of it; 
3.  The  product  has  not  the  qualitative  and 
quantitative  compowion  claimed  for  it; 
4.  Tests  on  the  finished  product  have  not 
been  carried  out; 
5.  Production  has  been  stopped  in  pursuance 
of  Article  7  of the  present directive. 
Chapter  V 
Miscellaneous provisions 
Article  10 
Any  decision  taken  under  the  terms  of  the 
present  directive  shall  be  accompanied  by  a 
precise  statement  of  grounds.  It  must  be 
notified  to  the  person  concerned,  with  an 
indication  of the procedure  for  appeal  under 
the existing law  and  of  the time-limit within 
which  such  appeal  must  be  lodged. 
Article  11 
No  order  for  the  permanent  or  temporary 
stoppage of manufacture, ban on  deliveries of 
the  product,  or  withdrawal  from  the  market 
may  be  made except for  the  reasons  stated  in 
the  present  directive. 
Article  12 
Member  States  shall  take  the necessary  meas-
ures  to  ensure  that  decisions  to  refuse  or 
withdraw  licences  for  sale,  to stop  manufac-
ture  permanently  or  to  withdraw  products 
from  the  market,  and  the  grounds  therefor 
shall immediately be brought to the notice  of 
the  other  Member  States. 
Chapter  VI 
Arrangements for implementation 
and  transitional  measures 
Article  13 
On  publication  of  the  present  directive,  the 
Commission,  in  collaboration  with  the  com-
petent authorities  of the Member States,  shall 
undertake the establishment of common stand-
ards  and  of  procedures  for  the  testing  of 
medicinal  preparations  as  provided  for  in 
Article  4(2),  point  8,  of  the  directive  of 
5  November  1962. 
Article  14 
The  Member  States  shall  enact  the necessary 
laws  and  regulations  to  conform  with  the 
provisions  of  the  present  directive  within 
twelve  months  of  its  notification  and  shall 
inform  the  Commission  immediately. 
The Member States  shall  inform the Commis-
sion,  in  time  for  it  to submit  comments,  of 
any  further  draft  laws  or  regulations  which 
they may contemplate adopting in  the matters 
covered  by  the  present  directive. 
Article  15 
The  regulations  provided  for  by  the  present 
directive  shall  be  applicable  to  products 
which  have  been  granted  a  licence  for  sale 
by  virtue  of  previous  provisions  two  years 
after the notification referred to in Article  14. 
Article  16 
The  present  directive  is  addressed  to  the 
Member  States. 
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